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Natural products are often large, synthetically intractable molecules, yet frequently offer surprising inroads into
previously unexplored chemical space for enzyme inhibitors. This work by Rush et al. shows how, aided by
detailed structural information, the large natural product chitinase inhibitor argifin can be dissected down to
a tiny 9 atom active fragment that can then be used as a scaffold to develop micromolar inhibitors for a chitinase
from the opportunistic pathogen Aspergillus fumigatus.BTZO-1 Reveals MIF’s ARE Secret
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Macrophage migration inhibitory factor (MIF), a ubiquitous protein, is a crit-
ical upstream regulator of the innate and acquired immune response;
however, its precise function in the majority of cells is not known. Here, Ki-
mura et al. clarify a mechanism of function of MIF using a small molecule
compound BTZO-1. BTZO-1, by interacting with MIF, activates the antiox-
idant response element (ARE) of glutathione S-transferase Ya subunit (GST
Ya) gene, and protects cardiomyocytes from oxidative insults. Stimulation
of MIF-mediated ARE activation by BTZO-1 derivatives may serve as
a strategy for the treatment of heart diseases.Through CYPome to New Fatty Acid Hydroxylase
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Cytochrome P450 enzymes are a superfamily of heme monooxygenases that play important physiological roles in the
biosynthesis of secondary metabolites and antibiotics, as well as in fatty acid oxidation. Sorangium cellulosum So
ce56, a producer of important secondary metabolites, is equipped with 21 putative P450 genes. Khatria et al. perform
a bioinformatic analysis of the P450s and reveal 9 novel bacterial P450 families. Since fatty acids play a pivotal role
during its complex life cycle, potential fatty acid hydroxylases were identified. This represents the initial report of
two autologous and one heterologous electron transfer paths for the subterminal hydroxylation of saturated fatty acids
by CYP109D1.Computer Power to Engineer
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Engineered biosynthetic pathways have potential to produce high-value molecules from inexpensive feedstocks, but
a key limitation is engineering enzymes with high activity and specificity. Here, Lippow et al. developed a method for
combining structure-based computational protein design with library-based enzyme screening. The key advance is to
take advantage of interresidue correlations favored by the design by encoding these amino-acid combinations (as well
as single-position preferences) into the library. This approach improves screening efficiency by at least two orders of
magnitude for engineering a novel glucose 6-oxidase enzyme, and these defined-sequence libraries will most likely be
broadly applicable in protein engineering.BBOX Inhibited!
PAGE 1316
The final step in carnitine biosynthesis is catalyzed by g-butyrobetaine (gBB) hydroxylase
(BBOX), an iron/2-oxoglutarate (2OG) dependent oxygenase. BBOX is inhibited by trime-
thylhydrazine-propionate (THP), a clinically used compound. Leung et al. report structural
and mechanistic studies on human BBOX and its reaction with THP. The results provide
a basis for development of improved BBOX inhibitors and may inspire the discovery of
new rearrangement reactions.Chemistry & Biology 17, December 22, 2010 ª2010 Elsevier Ltd All rights reserved v
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Defining protein interactions forms the basis for discovery of biological path-
ways, disease mechanisms, and opportunities for therapeutic intervention. To
harness the robust binding affinity and selectivity of structured peptides for inter-
actome discovery, Braun et al. engineered photoreactive stapled BH3 peptide
helices that covalently capture their physiologic BCL-2 family targets. The cross-
linking a helices covalently trap both static and dynamic protein interactors and
enable rapid identification of interaction sites, providing a critical link between in-
teractome discovery and targeted drug design.Of Nucleosomes and Cisplatin
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Todd and Lippard explore the effects of cisplatin binding to DNA at the nucleosome level to incorporate key features of
the eukaryotic nuclear environment. Site-specifically platinated nucleosomes carrying a 1,3-cis-{Pt(NH3)2}2+-d
(GpTpG) intrastrand cross-link were investigated using X-ray crystallography, in vitro nucleosome mobility assays,
and in vitro transcription experiments. The results from these studies provide new information about the effects of
cisplatin binding to nuclear DNA and enhance our understanding of the mechanism of transcription inhibition by plat-
inum anticancer compounds.LDL Receptor Gets a Small RNA Hit
PAGE 1344
Low-density lipoprotein receptor (LDLR) is a cell-surface receptor that
regulates cholesterol levels. Increased levels of LDLR would reduce
cholesterol levels and help treat hypercholesterolemia. Here Matsui
et al. show that duplex RNAs complementary to the promoter of LDLR
activate expression of LDLR and increase the display of LDLR on the
surface of liver cells. Activation can be achieved by chemically modified
duplex RNAs. Promoter-targeted duplex RNAs can overcome repres-
sion of LDLR expression by 25-hydroxycholesterol and do not interfere with activation of LDLR expression by lova-
statin. These data demonstrate that small RNAs can activate LDLR expression and affect LDLR function.Mycobacterial Galactan Biogenesis Drawn to a Halt
PAGE 1356
UDP-galactofuranose is a substrate for UDP-galactopyranosemutase and galactofuranosyltransferases, two enzymes
present in many pathogenic organisms but absent from mammals. In particular, these enzymes are involved in the
biosynthesis of a polymer essential for the survival of the causative agent of tuberculosis. Peltier et al. describe here
the synthesis of derivatives of UDP-Galf modified at C-5 and C-6 using a chemoenzymatic route. In cell-free assays,
these compounds prevented the formation of mycobacterial galactan via the production of short ‘‘dead-end’’ interme-
diates. Such compounds may ultimately facilitate the future development of new therapeutic agents against tubercu-
losis.2010 ª2010 Elsevier Ltd All rights reserved
